VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01132859 |
Recruitment Status
:
Recruiting
First Posted
: May 28, 2010
Last Update Posted
: October 19, 2017
|
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | May 27, 2010 | ||||
First Posted Date | May 28, 2010 | ||||
Last Update Posted Date | October 19, 2017 | ||||
Study Start Date | May 7, 2010 | ||||
Primary Completion Date | Not Provided | ||||
Current Primary Outcome Measures |
To evaluate blood and other tissue samples for immune responses to vacciness and natural infections. [ Time Frame: As indicated for evaluation of immune responses to particular infection and/or vaccination regimen ] | ||||
Original Primary Outcome Measures | Not Provided | ||||
Change History | Complete list of historical versions of study NCT01132859 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures | Not Provided | ||||
Original Secondary Outcome Measures | Not Provided | ||||
Current Other Outcome Measures | Not Provided | ||||
Original Other Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older | ||||
Official Title | VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older | ||||
Brief Summary | Background: - The Vaccine Research Center (VRC) is dedicated to understanding immune responses associated with prevention and treatment of infectious diseases. To study these immune responses, researchers need to collect specimens and images from individuals who have recently had a vaccination or recovered from an infection. These specimens and images are used to study different diseases and immune responses, and can be used to investigate ways to prevent or treat different medical conditions. Objectives: - To evaluate blood and other tissue samples for immune responses to vaccines and natural infections. Eligibility: - Healthy volunteers at least 18 years of age who agree to donate specimens for research purposes. Design:
Duration of participation is variable depending on the research question but will usually last up to 1 year. - Participants will be compensated for participation. |
||||
Detailed Description | Protocol Design: This is a specimen, imaging and data collection protocol designed with the purpose of understanding the immune responses to vaccines and infections in adult subjects through collection of tissue specimens and medical history data, and radiographic imaging. The information gained will enhance the knowledge of immune correlates of protection and will help in laboratory work related to the development and validation of immunological assays. This protocol will allow Vaccine Research Center (VRC) investigators and collaborators to evaluate tissue level immune responses in subjects who are recipients of Food and Drug Administration (FDA)-licensed vaccines, recipients of VRC clinical trials vaccines, control subjects, and naturally infected subjects as examples of naturally acquired immunity. Immune responses will be evaluated using blood, body fluids, mucosal and tissue samples, radiographic imaging and clinical evaluations. The underlying hypothesis for this protocol is that detailed studies of immune responses in blood and a diversity of tissue types, including a variety of mucosal surfaces, will further the understanding of immune responses following vaccination or recovery from an infectious disease and will advance development of vaccines against existing, new, and re-emerging pathogens. Subjects: Volunteers 18 years of age and older who agree to donate specimens for research purposes will be enrolled. A maximum of 500 subjects will be enrolled in the protocol. Study Plan: Subjects will receive information about study procedures and, if willing to participate, will sign the study informed consent. FDA-licensed vaccines may be administered to some study subjects as part of study participation. As per NIH Clinical Center (CC) policy, where appropriate, subjects will provide additional informed consent for study procedures. Duration: Individual subjects may donate samples as often as permitted by the protocol and NIH CC guidelines. The CC guidance on the volume of blood drawn and other inpatient/outpatient procedures will be followed. The protocol will undergo continuing review by the Institutional Review Board (IRB) annually. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Other Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Not Provided | ||||
Study Population | Not Provided | ||||
Condition | Immune System | ||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
500 | ||||
Original Estimated Enrollment | Same as current | ||||
Study Completion Date | Not Provided | ||||
Primary Completion Date | Not Provided | ||||
Eligibility Criteria |
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. Able and willing to complete the informed consent process. Willing to donate specimens for storage to be used for research and to have genetic tests performed for research purposes. EXCLUSION CRITERIA: Any medical, psychiatric, occupational condition or other condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions), use of anticoagulant medications for an ongoing medical condition, significant bruising or bleeding difficulties with IM injections or blood draws. [Note: Subjects taking anticoagulants, such as aspirin, prophylactically may be considered on a case to case basis.] |
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Senior) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT01132859 | ||||
Other Study ID Numbers | 100109 10-I-0109 |
||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product | Not Provided | ||||
IPD Sharing Statement | Not Provided | ||||
Responsible Party | Not Provided | ||||
Study Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | National Institutes of Health Clinical Center (CC) | ||||
Verification Date | August 17, 2017 |